

HBV Forum 8

June 21st, 2022
Merchant Taylors' Hall
30 Threadneedle Street
London EC2R 8JB, UK

12:00 PM		Registration & Lunch	
			<i>Veronica Miller, Forum for Collaborative Research</i>
1:00 PM	Introductory Remarks: HBV Forum Co-Chairs		<i>Oliver Lenz, Janssen Pharmaceuticals</i> <i>Marion Peters, Northwestern University</i>
Session I: Working Group and Regulatory Updates			
Moderator: Veronica Miller, Forum for Collaborative Research			
1:10 PM	CAM Nomenclature Working Group		<i>Harry Janssen, Erasmus Medical Center</i>
1:25 PM	Immune Monitoring Working Group		<i>Adam Gehring, Toronto Centre for Liver Disease</i>
1:40 PM	Regulatory Updates		<i>Virginia Sheikh, FDA</i>
2:10 PM	HBV Forum Webinar Series Recap		<i>Veronica Miller, Forum for Collaborative Research</i>
Session II: "Stopping Finite Treatment" Paper Presentation			
2:25 PM	Presentation		<i>Marion Peters, Northwestern University & Kosh Agarwal, King's College London</i>
2:50 PM	Session II Discussion and Audience Q&A		<i>All</i>
3:30 PM		Break	
Session III: Launch of HDV Co-Infection Working Group			
Moderators: Norah Terrault, University of Southern California & Heiner Wedemeyer, Medizinische Hochschule Hannover			
4:00 PM	Presentation		<i>Norah Terrault, University of Southern California & Heiner Wedemeyer, Medizinische Hochschule Hannover</i> <i>Stephanie Buchholz, BfArM</i> <i>Ingrid Choong, Eiger BioPharmaceuticals</i> <i>Carey Hwang, Vir Biotechnology</i> <i>Pietro Lampertico, University of Milan</i> <i>Virginia Sheikh, FDA</i> <i>Stephan Urban, University Hospital Heidelberg</i>
4:20 PM	Panel Discussion		
Session IV: The Role of Biomarkers in Drug Development			
Moderators: Oliver Lenz, Janssen Pharmaceuticals & Man-Fung Yuen, The University of Hong Kong			
5:00 PM	S Antigen Isoform and Immune Complexes Dynamics		<i>Gavin Cloherty, Abbott</i>
5:10 PM	Core-Related Antigen and HBV RNA		<i>Man-Fung Yuen, The University of Hong Kong</i> <i>Leen-Jan van Doorn, DDL Diagnostic Laboratory</i> <i>Adam Gehring, Toronto Centre for Liver Disease</i> <i>Melanie Paff, GSK</i>
5:20 PM	Panel Discussion		<i>Thomas Tu, Westmead Institute for Medical Research</i> <i>Jeffrey Wallin, Gilead</i> <i>Kathleen Whitaker, FDA</i> <i>Eric Donaldson, FDA</i>
6:00 PM		Adjourn and Evening Reception	
6:00 PM	HBV Forum Reception		
6:30 PM	HBV, PSC, and Liver Forums Reception		